secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2026-07-29T20:07:39+00:00
Accession:  0001127537-26-000035
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q2 revenue $22.8M (-5% YoY); net loss narrows to $10.1M
---------------------------------------------------------------

- Revenue $22.8M, down 5% YoY; U.S. $14.2M (-4%), international $8.6M (-6%; ex-China +12%).
- Record gross margin 78% (vs 72% YoY); operating expenses down 16% to $26.8M.
- Net loss $10.1M ($0.24/share) vs $15.2M loss; adjusted EBITDA loss $5.1M, down 39%.
- Cash $55.8M; FY2026 guidance: revenue $90-92M, gross margin ~76%, opex $109-111M.
- Management cites cost realignment and expects return to year-over-year revenue growth.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753726000035/0001127537-26-000035-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753726000035/lung-20260729.htm
  HTML page:      https://secwatch.observer/filing/0001127537-26-000035

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer